Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Georgy, Gehan S ^a   Nassar, Noha N ^b   Mansour, Hanaa A ^a   Abdallah, Dalaal M ^b  

^a NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CEREBROLYSIN; DOPAMINE; GLUCOSE; GLUTAMIC ACID; GLYCINE; HEMOGLOBIN A1C; INSULIN LIKE GROWTH FACTOR 1 BETA; NITRIC OXIDE; SEROTONIN; SOMATOMEDIN C; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINO ACID; INSULIN; NEUROPROTECTIVE AGENT; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN DEGENERATION; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; HYPERGLYCEMIA; IMMUNOREACTIVITY; LEARNING DISORDER; MALE; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; WEIGHT REDUCTION; ANIMAL; BRAIN; CHEMICALLY INDUCED; COGNITIVE DYSFUNCTION; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; MAZE TEST; MEMORY DISORDERS; METABOLISM; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

AMINO ACIDS; ANIMALS; BRAIN; COGNITIVE DYSFUNCTION; DIABETES MELLITUS, EXPERIMENTAL; INSULIN; MALE; MAZE LEARNING; MEMORY DISORDERS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 84879239626     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064847     Document Type: Article

References (69)

1. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7 (1):: 63-80.
2. Saravia F, Revsin Y, Lux-Lantos V, Beauquis J, Homo-Delarche F, et al. (2004) Oestradiol restores cell proliferation in dentate gyrus and subventricular zone of streptozotocin-diabetic mice. J Neuroendocrinol 16 (8):: 704-710.
3. Convit A, Wolf OT, Tarshish C, de Leon MJ, (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci 100 (4):: 2019-2022.
4. Arab L, Sadeghi R, Walker DG, Lue LF, Sabbagh MN, (2011) Consequences of aberrant insulin regulation in the brain: Can treating diabetes be effective for alzheimer's disease. Curr Neuropharmacol 9 (4):: 693-705.
5. Gillery P, (2001) Advanced glycation end products (AGEs), free radicals and diabetes. J Soc Biol 195 (4):: 387-390.
6. Rong LL, Gooch C, Szabolcs M, Herold KC, Lalla E, et al. (2005) RAGE: a journey from the complications of diabetes to disorders of the nervous system- striking a fine balance between injury and repair. Restor Neurol Neurosci 23 (5-6):: 355-365.
7. Baquer NZ, Taha A, Kumar P, McLean P, Cowsik SM, et al. (2009) A metabolic and functional overview of brain aging linked to neurological disorders. Biogerontology 10 (4):: 377-413.
8. Windisch M, Gschanes A, Hutter-Paier B, (1998) Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J Neural Transm Suppl 53: 289-298.
9. Allegri RF, Guekht A, (2012) Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Drugs Today 48 A: 25-41.
10. Garmanchuk LV, Perepelitsyna EM, Sidorenko M, Makarenko AN, Kul'chikov AE, (2009) Cytoprotective effect of neuropeptides on immunocompetent cells (in vitro study). Eksp Klin Farmakol 72 (4):: 28-32.
11. Tatebayashi Y, Lee MH, Li L, Iqbal K, Grundke-Iqbal I, (2003) The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathol 105: 225-232.
12. Serkina EV, Gromova OA, Torshin I, Sotnikova N, Nikonov AA, (2008) Cerebrolysin alleviates perinatal CNS disorders through the autoimmune modulation and antioxidant protection. Zh Nevrol PsikhiatrIm S SKorsakova 108 (11):: 62-66.
13. Plosker GL, Gauthier S, (2010) Spotlight on cerebrolysin in dementia. CNS Drugs 24 (3):: 263-266.
14. Masliah E, Díez-Tejedor E, (2012) The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today 48 A: 3-24.
15. Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS, (2012) Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS Neurol Disord Drug Targets 11 (1):: 40-49.
16. Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, et al. (2012) The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 39 (1):: 96-101.
17. Binder DK, Scharfman HE, (2004) Brain-derived neurotrophic factor. Growth Factors 22 (3):: 123-131.
18. Rockenstein E, Mante M, Adame A, Crews L, Moessler H, et al. (2007) Effects of cerebrolysin on neurogenesis in an APP transgenic model of alzheimer's disease. Acta Neuropathol 113 (3):: 265-275.
19. Eder P, Reinprecht I, Schreiner E, Skofitsch G, Windisch M, (2001) Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats. Histochem J33 (11-12):: 605-612.
20. ILAR (Institute of Laboratory Animal Resources) (1996) Guide for the Care and Use of Laboratory Animals. NIH Publication No. 85-23 (revised 1996). National Academy Press, Washington, D.C.
21. Ren J, Sietsma D, Qiu S, Moessler H, Finklestein SP, (2007) Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci 25 (1):: 25-31.
22. Ramachandran S, Asokkumar K, Uma Maheswari M, Ravi TK, Sivashanmugam AT, et al. (2011) Investigation of antidiabetic, antihyperlipidemic, and in vivo antioxidant properties of sphaeranthusindicuslinn in type 1 diabetic rats: An identification of possible biomarkers. Evid Based Complement Alternat Med 2011: 571721.
23. Sharma B, Singh N, (2011) Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology 215 (4):: 677-687.
24. Morris RG, (1984) Developments of a water maze producer for studying spatial learning in the rats. J Neurosci Meth 11: 47-60.
25. Narayanan SN, Kumar RS, Potu BK, Nayak S, Bhat PG, et al. (2010) Effect of radio-frequency electromagnetic radiations (RF-EMR) on passive avoidance behaviour and hippocampal morphology in Wistar rats. Ups J Med Sci 115 (2):: 91-96.
26. Trinder P, (1969) Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6: 24-25.
27. Bissé E, Abraham EC, (1985) New less temperature-sensitive microchromatographic method for the separation and quantitation of glycosylated hemoglobins using a non-cyanide buffer system. J Chromatog 344: 81-91.
28. Al-Shorbagy MY, El Sayeh BM, Abdallah DM, (2012) Diverse effects of variant doses of dexamethasonein lithium-pilocarpine induced seizures in rats. Can J Physiol Pharmacol 90: 13-21.
29. Ullah N, Lee HY, Naseer MI, Ullah I, Suh JW, et al. (2011) Nicotinamide inhibits alkylating agent-induced apoptotic neurodegeneration in the developing rat brain. PLoS One 6 (12):: e27093.
30. Heinrikson RL, Meredith SC, (1984) Amino acid analysis by reverse-phase high-performance liquid chromatography: precolumn derivatization with phenylisothiocyanate. Anal Biochem 136 (1):: 65-74.
31. Kontur P, Dawson R, Monjan A, (1984) Manipulation of mobile phase parameters for the HPLC separation of endogenous monoamines in rat brain tissue. J Neurosci Methods 11 (1):: 5-18.
32. Deniz S, Erdincler AS, Figen I, Tanju B, Gulden G, (1997) Lipid peroxidation and oxidant status in experimental animals: effect of aging and hypercholestrolemic diet. ClinActa 265: 77-84.
33. Prins HK, Loose JA (1969) Glutathione "chapter 4" Biochemical methods in red cell genetics. edited by J.Yanis. Academic Press, N.Y.D. London. pp.126-129.
34. Murali YK, Anand P, Tandon V, Singh R, Chandra R, et al. (2007) Long-term effects of Terminaliachebula Retz on hyperglycemia and associated hyperlipidemia, tissue glycogen content and in vitro release of insulin in streptozotocin induced diabetic rats. Exp Clin Endocrinol Diabetes 115 (10):: 641-646.
35. Kirana H, Jali MV, Srinivasan BP, (2011) The study of aqueous extract of Ficusreligiosa Linn on cytokine TNF-α in type 2 diabetic rats. Pharmacognosy Res 3 (1):: 30-34.
36. Alvarez XA, Sampedro C, Cacabelos R, Linares C, Aleixandre M, et al. (2009) Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin. Int J Neuropsychopharmacol 12 (7):: 867-872.
37. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, et al. (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69 (1):: 29-38.
38. Kuhad A, Sethi R, Chopra K, (2008) Lycopene attenuates diabetes-associated cognitive decline in rats. Life Sci 83 (3-4):: 128-134.
39. Sen S, Kar M, Roy A, Chakraborti AS, (2005) Effect of nonenzymatic glycation on functional and structural properties of hemoglobin. Biophys Chem 113 (3):: 289-298.
40. Kar M, Chakraborti AS, (1999) Release of iron from haemoglobin-a possible source of free radicals in diabetes mellitus. Indian J Exp Biol 37 (2):: 190-192.
41. Won SM, Lee JH, Park UJ, Gwag J, Gwag BJ, et al. (2011) Iron mediates endothelial cell damage and blood-brain barrier opening in the hippocampus after transient forebrain ischemia in rats. Exp Mol Med 43 (2):: 121-128.
42. Khan ZA, Chakrabarti S, (2007) Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp Diabetes Res 2007: 31867.
43. Baker BJ, Park KW, Qin H, Ma X, Benveniste EN, (2010) IL-27 inhibits OSM-mediated TNF-alpha and Inos gene expression in microglia. Glia 58 (9):: 1082-1093.
44. Pan W, Kastin AJ, (2001) Increase in TNF alpha transport after SCI is specific for time, region, and type of lesion. Exp Neurol 170 (2):: 357-363.
45. Ingaramo PI, Ronco MT, Francés DE, Monti JA, Pisani GB, et al. (2011) Tumor necrosis factor alpha pathways develops liver apoptosis in type 1 diabetes mellitus. MolImmunol 48 (12-13):: 1397-1407.
46. Lee YJ, Lee KH, Kim HR, Jessup JM, Seol DW, et al. (2001) Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 20 (12):: 1476-1485.
47. Kar M, Chakraborti AS, (1999) Release of iron from haemoglobin-a possible source of free radicals in diabetes mellitus. Indian J Exp Biol 37 (2):: 190-192.
48. Baydas G, Reiter RJ, Yasar A, Tuzcu M, Akdemir I, et al. (2003) Melatonin reduces glial reactivity in the hippocampus, cortex, and cerebellum of streptozotocin-induced diabetic rats. Free Radic Biol Med 35 (7):: 797-804.
49. Ahmad A, Rasheed N, Ashraf GM, Kumar R, Banu N, et al. (2012) Brain region specific monoamine and oxidative changes during restraint stress. Can J NeurolSci 39 (3):: 311-318.
50. Kim SE, Ko IG, Kim BK, Shin MS, Cho S, et al. (2010) Treadmill exercise prevents aging-induced failure of memory through an increase in neurogenesis and suppression of apoptosis in rat hippocampus. Exp Gerontol 45 (5):: 357-365.
51. Ono M, Itakura Y, Nonomura T, Nakagawa T, Nakayama C, et al. (2000) Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice. Metabolism 49 (1):: 129-133.
52. Yan H, Mitschelen M, Bixler GV, Brucklacher RM, Farley JA, et al. (2011) Circulating IGF1 regulates hippocampal IGF1 levels and brain gene expression during adolescence. J Endocrinol 211 (1):: 27-37.
53. Bouché C, Serdy S, Kahn CR, Goldfine AB, (2004) The cellular fate of glucose and its relevance in type 2 diabetes. Endocrine Reviews 25 (5):: 807-830.
54. Long LH, Halliwell B, (2009) Artefacts in cell culture: pyruvate as a scavenger of hydrogen peroxide generated by ascorbate or epigallocatechingallate in cell culture media. Biochem Biophys Res Commun 388: 700-704.
55. Miura Y, Misawa N, Kawano Y, Okada H, Inagaki Y, et al. (2003) Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection. Proc Natl Acad Sci USA 100 (5):: 2777-2782.
56. Sharma HS, Zimmermann-Meinzingen S, Johanson CE, (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat. Ann N Y Acad Sci 1199: 125-137.
57. Francis PT, Ramírez MJ, Lai MK, (2010) Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 59 (4-5):: 221-229.
58. Lesemann A, Reinel C, Hühnchen P, Pilhatsch M, Hellweg R, et al. (2012) MPTP-induced hippocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice. Brain Res 1457: 51-69.
59. Winner B, Geyer M, Couillard-Despres S, Aigner R, Bogdahn U, et al. (2006) Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol 197 (1):: 113-121.
60. Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W, (1999) Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 62: 239-245.
61. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, et al. (2003) The neuroprotective effects of cerebrolysin trade mark in a transgenic model of alzheimer's disease are associated with improved behavioral performance. J Neural Transm 110: 1313-1327.
62. Marcussen AB, Flagstad P, Kristjansen PE, Johansen FF, Englund U, (2008) Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurol Scand 117 (2):: 94-100.
63. Denis I, Potier B, Vancassel S, Heberden C, Lavialle M, (2013) Omega-3fattyacids and brain resistance to ageing and stress: Body of evidence and possible mechanisms. Ageing Res Rev 12 (2):: 579-594.
64. Hu NW, Ondrejcak T, Rowan MJ, (2012) Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol Biochem Behav 100 (4):: 855-862.
65. Rodríguez JJ, Noristani HN, Verkhratsky A, (2012) The serotonergic system in ageing and Alzheimer's disease. Prog Neurobiol 99 (1):: 15-41.
66. Shonesy BC, Thiruchelvam K, Parameshwaran K, Rahman EA, Karuppagounder SS, et al. (2012) Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents. Neurobiol Aging 33 (2):: 430.e5-18.
67. Errico F, Nisticò R, Napolitano F, Mazzola C, Astone D, et al. (2011) Increased D-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiol Aging 32 (12):: 2229-2243.
68. López OL, DeKosky ST, (2003) Neuropathology of Alzheimer's disease and mild cognitive impairment. Rev Neurol 37 (2):: 155-163.
69. Comim CM, Reis PA, Frutuoso VS, Fries GR, Fraga DB, et al. (2012) Effects of experimental cerebral malaria in memory, brain-derived neurotrophic factor and acetylcholinesterase activity [correction for acitivity] in the hippocampus of survivormice. NeurosciLett 523 (2):: 104-107.